Beroni Group Limited

NSX:BTG ISIN:AU000000BTG8

Beroni GroupBeroni Group (NSX:BTG) (OTCMKTS:BNIGF) is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of a US FDA approved virus diagnostic kit, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. To learn more about Beroni, please visit www.beronigroup.com.

  

News

Beroni Group Limited (NSX:BTG) Launches a New Probiotics Health Product

🕔11/10/2020 2:45:00 PM 1046

Beroni Group (OTCMKTS:BNIGF) (NSX:BTG), an Australia-based diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, announces the launch of a new product "Beilemei" in China.

Read Full Article

Beroni Group Limited (NSX:BTG) Named Top Infection Control Solutions Company

🕔11/9/2020 4:06:00 PM 716

Beroni Group (OTCMKTS:BNIGF) (NSX:BTG), an Australia-based diversified biopharmaceutical enterprise, announced that the Company has been recognized as one of the 2020's infection control solutions companies in Asia Pacific by MedTech Outlook.

Read Full Article

Beroni Group Limited (NSX:BTG) Successful Completion of SARS-CoV-2 Assay

🕔10/19/2020 2:20:00 PM 1339

Beroni Group (OTCMKTS:BNIGF) (NSX:BTG), an Australia-based diversified biopharmaceutical enterprise, today announces successful completion of SARS-CoV-2 pseudovirus neutralization assay in collaboration with GenScript Biotech Corporation (HKSE:1548).

Read Full Article

Beroni Group Limited (NSX:BTG) Receives COVID-19 Test Kits Commercial Order

🕔9/8/2020 11:21:00 AM 2253

Beroni Group (OTCQX:BNIGF) (NSX:BTG) today announced that it received the first commercial order for its proprietarily developed SARS-CoV-2 Antibody Detection Kit from Forsitech Inc., a pharmaceutical trading company based in Japan.

Read Full Article

Beroni Group Limited (NSX:BTG) Signs Agreement with Genscript Biotech

🕔8/12/2020 2:10:00 PM 1469

Beroni Group (OTCMKTS:BNIGF) (NSX:BTG) is pleased to announce that further to its announcement on August 4, 2020 regarding the development of a medical solution utilizing nanobody technology for COVID-19, it has just signed an agreement with GenScript Biotech Corporation

Read Full Article

Beroni Group Limited (NSX:BTG) Constructed Nanobodies for Coronavirus

🕔8/4/2020 2:30:00 PM 1349

Beroni Group (OTCMKTS:BNIGF) (NSX:BTG) today announced its further progress on the development of a medical solution using nanobody technology for the COVID-19 coronavirus in collaboration with Tianjin University in China.

Read Full Article

Beroni Group Limited (NSX:BTG) Beroni to Supply COVID-19 Antibody Test Kit to Japan

🕔7/10/2020 3:00:00 PM 1387

Beroni Group (OTCMKTS:BNIGF) (NSX:BTG) is pleased to announce that it is collaborating with Forsitech Inc. and Standard Capital Co., Ltd to supply its SARS-CoV-2 total antibody detection kit for clinical testing in the Japanese market.

Read Full Article

Beroni Group Limited (NSX:BTG) Dr Richard Buchta Appointed as Director

🕔6/30/2020 11:37:00 AM 1600

Beroni Group (OTCMKTS:BNIGF) (NSX:BTG) is pleased to announce that it has appointed Dr. Richard Buchta as an independent non-executive director of the Company

Read Full Article

Beroni Group Limited (NSX:BTG) Issue of shares

🕔6/23/2020 7:14:00 AM 1768

Beroni Group (OTCMKTS:BNIGF) (NSX:BTG) is pleased to announce that, the Company has completed the issue of 2,390,000 fully paid ordinary shares to the Directors, employees and scientists.

Read Full Article

Beroni Group Limited (NSX:BTG) Issue of US$2.97m Convertible Notes to Fund Growth

🕔6/9/2020 1:07:00 PM 1448

Beroni Group (OTCMKTS:BNIGF) (NSX:BTG), an international diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, is pleased to announce that it has raised US$2.97 million via the issue of convertible notes to professional and sophisticated investors in Japan.

Read Full Article
###

2,905 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 31) (Last 30 Days: 114) (Since Published: 2912) 

Company Data

    Headquarters
  • Suite 401, 447 Kent Street
    Sydney, NSW 2000
    Australia
  • Telephone
  • +61 2 8051 3055 
  • Principal Sector
  • Biotech 
  • Principal Industry
  • Pharmaceutical 
  • Homepage
  • www.beronigroup.com

Social Media